Pharmala Biotech Holdings Inc. (CSE:MDMA)

Market Cap	10.35M -62.4%
Revenue (ttm)	754.64K +121.9%
Net Income	-2.11M
EPS	-0.02
Shares Out	108.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,500
Average Volume	50,875
Open	0.1050
Previous Close	0.1050
Day's Range	0.0950 - 0.1050
52-Week Range	0.0850 - 0.2000
Beta	0.77
RSI	42.64
Earnings Date	Apr 29, 2026

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Kadysh
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MDMA

Financial Performance

In fiscal year 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.